In this episode, Medicom’s correspondent covers 5 presentations from the European Haematology Association (EHA), held 9-17 June 2021. The topics discussed are:
- ELEVATE-TN 4-year follow-up: Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia.
- Immuno-oncology agents effective in treating classic Hodgkin's lymphoma.
- GLOW trial: Fixed-duration ibrutinib + venetoclax was a superior treatment in older or unfit patients with chronic lymphocytic leukaemia compared with chlorambucil + obinutuzumab. These data support the positive clinical profile of all-oral, once-daily, fixed-duration ibrutinib plus venetoclax as first-line treatment for this patient population.
- In patients with newly diagnosed multiple myeloma, daratumumab with standard-of-care (i.e. lenalidomide and dexamethasone) achieved superior outcomes in OS, PFS and ORR compared with standard of care alone, as demonstrated by the interim overall survival results of the phase 3 MAIA trial.
- The phase 2 BEYOND study demonstrated the safety and efficacy of luspatercept in patients with non-transfusion-dependent β-thalassaemia.
Posted on
Previous Article
« Investigational oral medication may help combat postpartum depression Next Article
Timely second COVID shot especially important for rheumatoid arthritis patients »
« Investigational oral medication may help combat postpartum depression Next Article
Timely second COVID shot especially important for rheumatoid arthritis patients »
Table of Contents: EHA 2021
Featured articles
Lymphoma
Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma
MATRix with ASCT: best long-term survival for primary CNS lymphoma
Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma
The journey ahead for CAR T-cell therapy in r/r follicular lymphoma
ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome
Promising chemo-free treatment options in r/r DLBCL
Leukaemia
Sabatolimab achieved durable responses in patients with high-risk MDS and AML
Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia
Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL
Oral azacitidine improves overall survival in patients with acute myeloid leukaemia
Reduced-intensity conditioning ASCT is effective in older patients with AML
ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib
Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL
GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment
Myeloma and Myelofibrosis
Novel targets in myelofibrosis: overview of emergent therapies
Immune therapy of multiple myeloma
MAIA results confirm superior efficacy of daratumumab with standard-of-care
ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis
Thrombotic and Thrombocytopenic Disorders including COVID-19 related
Acquired TTP: new treatments and updated guidelines
Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia
Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura
Physiopathology of coagulopathy in haematological malignancies and COVID-19
Haemostatic abnormalities are associated with mortality in COVID-19
Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis
Haemoglobinopathies
Luspatercept improved anaemia in patients with non-transfusion-dependent β-thalassaemia
Personalising treatment for sickle cell disease
Gene therapy: A promising approach for hereditary haemoglobinopathies
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com